Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
2,208 results
  • Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. [Review]
    NPJ Breast Cancer 2019; 5:34Page DB, Bear H, … Adams S
  • Antibodies blocking programmed death 1 (anti-PD-1) or its ligand (anti-PD-L1) are associated with modest response rates as monotherapy in metastatic breast cancer, but are generally well tolerated and capable of generating dramatic and durable benefit in a minority of patients. Anti-PD-1/L1 antibodies are also safe when administered in combination with a variety of systemic therapies (chemotherap…
  • Update on the Guideline of Guidelines: Non-Muscle Invasive Bladder Cancer. [Review]
    BJU Int 2019Taylor J, Becher E, Steinberg GD
  • Non-muscle invasive bladder cancer (NMIBC) is the most common form of bladder cancer with frequent recurrences and risk for progression. Risk stratified treatment and surveillance protocols are often utilized to guide management. In 2017, this journal reviewed guidelines on NMIBC from four major organizations: the American Urological Association (AUA)/ Society of Urologic Oncology (SUO), the Euro…
  • The Evolution of Spiritual Care in the NCCN Distress Management Guidelines. [Review]
    J Natl Compr Canc Netw 2019; 17(10):1257-1261Handzo G, Bowden JM, King S
  • Spiritual care and chaplaincy have been part of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Distress Management since the first meeting of the panel in 1997, possibly the first time this degree of spiritual care and chaplaincy care integration occurred in cancer care. Since that time, the chaplaincy care section of the guidelines, especially chaplain assessment categor…
  • Update on the Implementation of NCCN Guidelines for Distress Management by NCCN Member Institutions. [Review]
    J Natl Compr Canc Netw 2019; 17(10):1251-1256Donovan KA, Deshields TL, … Riba MB
  • The first NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Distress Management were published in 1999. Since then, a number of other organizations have advocated for distress screening. Previous surveys of distress screening showed modest progress in implementation of the NCCN Guidelines for Distress Management by NCCN Member Institutions (MIs); this review examined whether fur…
  • NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. [Journal Article]
    J Natl Compr Canc Netw 2019; 17(10):1154-1165Kumar SK, Callander NS, … Kumar R
  • The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy of renal significance, solitary plasmacytoma, smoldering myeloma, and multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates and changes in the 1.2020 version of the NCCN Guidelines for Multiple …
  • Distress Management, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. [Journal Article]
    J Natl Compr Canc Netw 2019; 17(10):1229-1249Riba MB, Donovan KA, … Darlow SD
  • Distress is defined in the NCCN Guidelines for Distress Management as a multifactorial, unpleasant experience of a psychologic (ie, cognitive, behavioral, emotional), social, spiritual, and/or physical nature that may interfere with the ability to cope effectively with cancer, its physical symptoms, and its treatment. Early evaluation and screening for distress leads to early and timely managemen…
New Search Next